James Czirr, Executive Chairman of Galectin Therapeutics (NASDAQ: GALT),
the leading developer of therapeutics that target galectin proteins to
treat fibrosis and cancer, will be a guest on "The RedChip Money
Report"™ television program featuring emerging growth companies on FOX
Business News, Saturday, February 9, 2013 at 2:30 p.m. Eastern.
"The RedChip Money Report"™ delivers insightful commentary on small-cap
investing, interviews with Wall Street analysts, financial book reviews,
as well as featured interviews with executives of public companies. The
show is hosted by Dave Gentry, a leading authority on small-cap stocks
and president of RedChip, an international small-cap research firm and
an Inc. 5000 company. The program airs in a paid programming block with
the network http://www.redchip.com/media/mediamain.asp page=redchiptv&pl=PLgBW00-WEinAN4lnGanOG7hEJALqRJzAi&from=services.
WHO: James Czirr, Executive Chairman, Galectin
WHAT: FOX Business News "The RedChip Money Report"
WHEN: Saturday, February 9, 2013, 2:30 PM, Eastern
About Galectin Therapeutics
Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease
and cancer based on the Company's unique understanding of galectin
proteins, key mediators of biologic function. We are leveraging
extensive scientific and development expertise as well as established
relationships with external sources to achieve cost effective and
efficient development. We are pursuing a clear development pathway to
clinical enhancement and commercialization for our lead compounds in
liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
[ Back To NFVZone's Homepage ]